Sanofi (SNY) Cash from Restructuring (2009 - 2016)

Sanofi has disclosed Cash from Restructuring across 8 years of filings, most recently posting -$551.5 million for Q1 2016.

• Cash from Restructuring for Q1 2016 came in at -$551.5 million, down 38.28% year-over-year; the trailing twelve-month figure through Mar 2016 was -$1.0 billion (down 411.34% YoY), and the FY2015 annual result was -$398.8 million, down 172.99% from the prior year.
• Cash from Restructuring came in at -$551.5 million for Q1 2016 at Sanofi, down from -$393.5 million in the prior quarter.
• In the past five years, Cash from Restructuring ranged from a high of $1.5 billion in Q4 2012 to a low of -$551.5 million in Q1 2016.
• The 5-year median for Cash from Restructuring is $69.9 million (2014), against an average of $49.3 million.
• Across the five-year window, Cash from Restructuring surged 241.31% in 2012 and sank 670.67% in 2015, its largest moves.
• Sanofi's Cash from Restructuring stood at $1.5 billion in 2012, then slumped by 72.41% to $408.3 million in 2013, then tumbled by 133.36% to -$136.2 million in 2014, then plunged by 188.85% to -$393.5 million in 2015, then sank by 40.15% to -$551.5 million in 2016.
• The last three Cash from Restructuring figures came in at -$551.5 million (Q1 2016), -$393.5 million (Q4 2015), and -$64.5 million (Q3 2015), per Business Quant data.